|
|
Vol. 25.32 – 21 October, 2024
|
|
|
|
|
|
|
|
A Phase III EMBARK study aimed to assess the efficacy and safety of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy was conducted. [Nature Medicine]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Investigators reported the development and therapeutic performance of CAR constructs leveraging protein binders computationally designed de novo to have high affinity for the epidermal growth factor receptor or the tumor-associated antigen CD276, which were overexpressed in glioblastoma.
[Nature Biomedical Engineering]
|
|
|
|
|
|
Leveraging a Phase I clinical trial of the gamma-secretase inhibitor, crenigacestat, with anti-BCMA CAR T cells, researchers utilized single-nuclei RNA sequencing and Assay for Transposase-Accessible Chromatin sequencing to characterize the effects of gamma-secretase inhibitor on the tumor microenvironment.
[Blood]
|
|
|
|
|
|
Targeting of reporter genes revealed extended interference in P. oleovorans and Escherichia coli cells producing recombinant CRISPR ribonucleoprotein complexes.
[Nucleic Acids Research]
|
|
|
|
|
|
The authors reported the design and functionality of transient CAR T cells with selectivity to oncofetal chondroitin sulfate.
[EMBO Molecular Medicine]
|
|
|
|
|
|
Mice were placed on an ω-6-rich high-fat diet or a lean control diet and underwent destabilization of the medial meniscus to induce osteoarthritis. Obesity and joint injury significantly increased cellular senescence in subcutaneous and visceral fat as well as joint tissues such as synovium and cartilage.
[Proceedings of The National Academy of Sciences of The United States of America]
|
|
|
|
|
|
Researchers assessed the engraftment dynamics of various human immune cells over time and monitored the development of graft-versus-host disease in both models. [Journal For Immunotherapy of Cancer]
|
|
|
|
|
|
Investigators reported 14 cases of immune effector cell-associated enterocolitis following CAR-T therapy in multiple myeloma, with a 1.2% incidence overall.
[Blood Cancer Journal]
|
|
|
|
|
|
Investigators used a novel mitochondrial pyruvate carrier inhibitor, MITO-66, which robustly induced a stem cell-like memory phenotype in CD19-CAR T cells generated from healthy donors and patients with relapsed/refractory B cell malignancies. [Molecular Therapy Oncology]
|
|
|
|
|
|
|
|
|
With all the remarkable new approaches to treat neurological disorders, the authors take a critical look at the state of current clinical trials and how challenges may be overcome with the evolving technology and innovation occurring in the stem cell field.
[Nature Medicine]
|
|
|
|
|
|
The development and advancement of these novel therapies raise questions regarding the ongoing role of HSCT in the management of R/R DLBCL and the best sequence of cellular and bispecific therapies to optimize patients’ outcomes.
[Haematologica]
|
|
|
|
|
|
Scientists focus on the clinical development of Roctavian for which the collective clinical trials represent the largest body of work thus far available for any licensed adeno-associated virus product. [Blood Advances]
|
|
|
|
|
|
|
|
Cancer Research UK has invested in an institute outside of London to accelerate advancement in personalized medicine and early detection, The University of Cambridge has announced it will open a new facility to deliver CAR-T cell therapies, enabling more treatments for patients.
[Cancer Research UK (RegenMedNet)]
|
|
|
|
|
|
A new state-of-the-art laboratory is set to open at Addenbrooke’s Hospital that will deliver ‘home-grown’ CAR-T cells to help improve treatment for blood cancers. [NHS]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
University of Wisconsin Madison – Madison, Wisconsin, United States
|
|
|
|
|
|
|
Bristol-Myers Squibb – Seattle, Washington, United States
|
|
|
|
|
|
|
Baylor College of Medicine – Houston, Texas, United States
|
|
|
|
|
|
|
Bristol-Myers Squibb – Seattle, Washington, United States
|
|
|
|
|
|
|
TU Dresden – Dresden, Germany
|
|
|
|
|
|